Panchal K, Nihalani B, Oza U, Panchal A, Shah B. Exploring the mechanism of action bitter melon in the treatment of breast cancer by network pharmacology. World J Exp Med 2023; 13(5): 142-155 [PMID: 38173546 DOI: 10.5493/wjem.v13.i5.142]
Corresponding Author of This Article
Bhumi Shah, PhD, Associate Professor, Pharmaceutical Chemistry, L. J. Institute of Pharmacy, L J University, Sanand Circle, Sarkhej-Gandhinagar Hwy, Sarkhej, Gujarat, Ahmedabad 382210, India. bhumi197@gmail.com
Research Domain of This Article
Integrative & Complementary Medicine
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Exp Med. Dec 20, 2023; 13(5): 142-155 Published online Dec 20, 2023. doi: 10.5493/wjem.v13.i5.142
Exploring the mechanism of action bitter melon in the treatment of breast cancer by network pharmacology
Kavan Panchal, Bhavya Nihalani, Utsavi Oza, Aarti Panchal, Bhumi Shah
Kavan Panchal, Bhavya Nihalani, Utsavi Oza, Aarti Panchal, Bhumi Shah, Pharmaceutical Chemistry, L. J. Institute of Pharmacy, L J University, Gujarat, Ahmedabad 382210, India
Author contributions: Panchal K designed, performed and wrote the paper; Nihalani B designed, performed and wrote the paper; Oza U edited the paper; Panchal A edited the paper; Shah B designed, supervised and edited the paper.
Conflict-of-interest statement: The authors declare no conflicts of interest in this paper.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bhumi Shah, PhD, Associate Professor, Pharmaceutical Chemistry, L. J. Institute of Pharmacy, L J University, Sanand Circle, Sarkhej-Gandhinagar Hwy, Sarkhej, Gujarat, Ahmedabad 382210, India. bhumi197@gmail.com
Received: September 22, 2023 Peer-review started: September 22, 2023 First decision: September 29, 2023 Revised: October 4, 2023 Accepted: October 30, 2023 Article in press: October 30, 2023 Published online: December 20, 2023
Core Tip
Core Tip: The phytochemicals and molecular processes in bitter melon that are thought to be involved in the therapy of breast cancer (BRCA) were investigated using network Pharmacology. Our research demonstrated that the anti-BRCA benefits of bitter melon are likely caused by negative regulation of transcription, cell differentiation, apoptosis, proteolysis, negative control of neuron apoptosis, and cell migration. Further discovered nine important pathways like phosphatidylinositol 3-kinase/protein kinase B signaling, transcriptional dysregulation, axon guidance, calcium signaling, focal adhesion, janus kinase-signal transducer and activator of transcription signaling, cyclic adenosine monophosphate signaling, mammalian target of rapamycin signaling, and phospholipase D signaling, are likely to be involved in the mechanism of action of bitter melon for the treatment of BRCA.
